Recombinant Lectin Production for SARS-CoV-2 Immunity

The patent creates recombinant copies of the lectin protein using synthetic biology approaches. The lectin gene is cloned into expression vectors and expressed in heterologous systems (bacteria, yeast, or plant cells), producing large quantities of identical lectin copies without relying on natural plant extraction. This copying approach enables high-volume production while maintaining the anti-viral activity of the original lectin.

The patent replaces the mechanical extraction process from plant tissues with a biochemical production system. Instead of physically extracting lectins from plant materials (which yields low concentrations), the system uses recombinant DNA technology and cellular expression machinery to produce lectins biochemically, achieving high-volume production with concentrated output.

The patent employs a simpler, more scalable production system using recombinant lectins that can be manufactured at lower cost with fewer regulatory hurdles compared to traditional vaccines. The lectins are produced in microbial or plant cell systems that are easier and cheaper to scale, making the therapy more accessible globally while maintaining protective efficacy through innate immune activation.

Instead of using complex vaccine approaches that require trained adaptive immunity, the patent inverts the approach by using simple lectin proteins that directly activate innate immune pathways. This inversion simplifies the mechanism of action, reducing manufacturing complexity and improving accessibility while still achieving protective immunity through a different immunological pathway.